Effect of Changing the Method of Taking Dabigatran on Gastrointestinal Adverse Events

DOI Web Site 1 Citations 11 References
  • Yukita Takumi
    Hokkaido PWFAC, Abashiri Kosei General Hospital, Department of Hospital Pharmacy<sup></sup>
  • Hiura Kazuya
    Hokkaido PWFAC, Abashiri Kosei General Hospital, Department of Hospital Pharmacy<sup></sup>
  • Fuchigami Shunsuke
    Hokkaido PWFAC, Abashiri Kosei General Hospital, Department of Hospital Pharmacy<sup></sup>
  • Azuchi Nami
    Hokkaido PWFAC, Abashiri Kosei General Hospital, Department of Hospital Pharmacy<sup></sup>
  • Suyama Akina
    Hokkaido PWFAC, Abashiri Kosei General Hospital, Department of Hospital Pharmacy<sup></sup>
  • Inagaki Takahiro
    Hokkaido PWFAC, Mukawa Kosei Hospital, Department of Hospital Pharmacy
  • Imai Takahito
    Hokkaido PWFAC, Abashiri Kosei General Hospital, Department of Hospital Pharmacy<sup></sup>
  • Watanabe Hiroaki
    Hokkaido PWFAC, Abashiri Kosei General Hospital, Department of Hospital Pharmacy<sup></sup>

Bibliographic Information

Other Title
  • ダビガトランの服用方法が消化器系有害事象に及ぼす影響

Search this article

Description

Upper gastrointestinal symptoms, a common adverse effect of dabigatran, influence the continuation of medication. It has been speculated that this adverse effect can be reduced by changing the method of taking dabigatran: that is, to instruct patients to swallow dabigatran capsules whole with a glassful of water. However, there is no evidence to support this conclusion. Therefore, we changed our patient compliance instruction of dabigatran to the method mentioned above from September 2013 and investigated the effect of that change on the onset of adverse events and patient quality of life (QOL). Among 42 patients treated with dabigatran, 17 patients were categorized into the instruction change group and 25 were categorized into the no instruction change group. The Izumo scale was used to assess patient QOL. A total of 20 patients experienced side effects in the upper gastrointestinal tract (6 in the instruction change group, and 14 in the no instruction change group), and 18 patients in the lower gastrointestinal tract (3 in the instruction change group, and 15 in the no instruction change group). Izumo scale scores were significantly lower in the instruction change group than in the no instruction change group. Furthermore, in the no instruction change group, 5 patients showed a remarkable decrease in patient QOL by the adverse effects of gastrointestinal symptoms; however, in the instruction change group, this did not occur in any patients. The results indicate that patient QOL can be maintained by altering the method of taking dabigatran.

Journal

Citations (1)*help

See more

References(11)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top